{"id":398840,"date":"2020-12-14T08:03:21","date_gmt":"2020-12-14T13:03:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398840"},"modified":"2020-12-14T08:03:21","modified_gmt":"2020-12-14T13:03:21","slug":"portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/","title":{"rendered":"Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors"},"content":{"rendered":"
\n

\n Click <\/em>
\n
\n
\n here<\/u>
\n <\/em>
\n <\/a>
\n to join the case<\/em>\n <\/p>\n

LOS ANGELES, Dec. 14, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm<\/u><\/a> advises investors that a class action lawsuit has been filed on behalf of Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA) investors that acquired securities between\u00a0October 15, 2019 and August 7, 2020.\u00a0\u00a0<\/p>\n

Investors are encouraged to contact attorney Lesley F. Portnoy<\/u><\/a>,<\/u> to determine eligibility to participate in this action, by phone 310-692-8883 or email<\/u><\/a>, or click here<\/u><\/a> to join the case.<\/p>\n

It is alleged in the complaint that Reata made misleading and false statements to the market. Reata failed to produce MOXIe Part 2 study results from the FDA that were sufficient to support the marketing of approval for omaveloxolone for the treatment of FA without additional evidence. Based on the MOXIe Part 2 study alone, it was foreseeable that omaveloxolone would not be approved by the FDA for the treatment of FA. Reata\u2019s public statements were false and materially misleading throughout the class period, based on these facts. Investors suffered damages when the market learned the truth about Reata.<\/p>\n

Please visit our website<\/u><\/a> to review more information and submit your transaction information.<\/p>\n

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm\u2019s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com<\/u><\/a>
310-692-8883
www.portnoylaw.com<\/p>\n

Attorney Advertising<\/p>\n

\n \n <\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Click here to join the case LOS ANGELES, Dec. 14, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA) investors that acquired securities between\u00a0October 15, 2019 and August 7, 2020.\u00a0\u00a0 Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. It is alleged in the complaint that Reata made misleading and false statements to the market. Reata failed to produce MOXIe Part 2 study results from the FDA that were sufficient to support the marketing of approval for omaveloxolone for … <\/p>\n

Continue reading “Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-398840","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPortnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Click here to join the case LOS ANGELES, Dec. 14, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA) investors that acquired securities between\u00a0October 15, 2019 and August 7, 2020.\u00a0\u00a0 Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. It is alleged in the complaint that Reata made misleading and false statements to the market. Reata failed to produce MOXIe Part 2 study results from the FDA that were sufficient to support the marketing of approval for omaveloxolone for … Continue reading "Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-14T13:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTExNSMzODY4MzQ2IzIxOTU1Mjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors\",\"datePublished\":\"2020-12-14T13:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/\"},\"wordCount\":251,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTExNSMzODY4MzQ2IzIxOTU1Mjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/\",\"name\":\"Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTExNSMzODY4MzQ2IzIxOTU1Mjc=\",\"datePublished\":\"2020-12-14T13:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTExNSMzODY4MzQ2IzIxOTU1Mjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTExNSMzODY4MzQ2IzIxOTU1Mjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/","og_locale":"en_US","og_type":"article","og_title":"Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors - Market Newsdesk","og_description":"Click here to join the case LOS ANGELES, Dec. 14, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA) investors that acquired securities between\u00a0October 15, 2019 and August 7, 2020.\u00a0\u00a0 Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. It is alleged in the complaint that Reata made misleading and false statements to the market. Reata failed to produce MOXIe Part 2 study results from the FDA that were sufficient to support the marketing of approval for omaveloxolone for … Continue reading \"Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-14T13:03:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTExNSMzODY4MzQ2IzIxOTU1Mjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors","datePublished":"2020-12-14T13:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/"},"wordCount":251,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTExNSMzODY4MzQ2IzIxOTU1Mjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/","name":"Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTExNSMzODY4MzQ2IzIxOTU1Mjc=","datePublished":"2020-12-14T13:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTExNSMzODY4MzQ2IzIxOTU1Mjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTExNSMzODY4MzQ2IzIxOTU1Mjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portnoy-law-lawsuit-filed-on-behalf-of-reata-pharmaceuticals-inc-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Portnoy Law: Lawsuit Filed On Behalf of Reata Pharmaceuticals, Inc. Investors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=398840"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398840\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=398840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=398840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=398840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}